Improved statistical analysis of moclobemide dose effects on panic disorder treatment

European Archives of Psychiatry and Clinical Neuroscience

Volumn 260, Issue 3, 2010, Pages 243-248

  Ross, Donald C ^a   Klein, Donald F ^a,b   Uhlenhuth, E H ^c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Analysis of covariance; Maximum likelihood; Panic disorder; Slope estimation

Indexed keywords

MOCLOBEMIDE;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; MAXIMUM LIKELIHOOD METHOD; OUTCOME ASSESSMENT; OUTPATIENT CARE; PANIC; PRIORITY JOURNAL; REPEAT PROCEDURE; SENSITIVITY ANALYSIS;

ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MOCLOBEMIDE; PANIC DISORDER; REGRESSION ANALYSIS;

EID: 77950864491     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-009-0062-9     Document Type: Article

References (18)

1. M Da Prada L Pieri AM Cesura, et al. 1994 The pharmacology of moclobemide Rev Contemp Pharmacother 5 1 18
2. Dixon WJ (1992) BMDP statistical software manual. University of California Press, Berkeley
3. J Dingemanse N Wood T Guentert, et al. 1998 Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects Psychopharmacology 140 164 172 10.1007/s002130050754 1:CAS:528:DyaK1MXis1Kg 9860107 (Pubitemid 28538476)
4. International Multicenter Clinical Trial Group 1997 Moclobemide in social phobia: a double-blind, placebo-controlled study Eur Arch Psychiatry Clin Neurosci 247 71 80 10.1007/BF02900196 (Pubitemid 27193015)
5. PE Keck Jr SL McElroy 1997 New uses for antidepressants: social phobia J Clin Psychiatry 141 32 36
6. DF Klein DC Ross 1993 Reanalysis of the national institute of mental health treatment of depression collaborative research program general effectiveness report Neuropsychopharmacology 8 241 251 1:STN:280: DyaK3s3ot12lsg%3D%3D 8507351
7. B Loerch M Graf-Morgenstern M Haautzinger, et al. 1999 Randomized placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia Br J Psychiatry 174 205 212 10.1192/bjp.174.3.205 1:STN:280:DyaK1MznslGmsQ%3D%3D 10448444 (Pubitemid 29147234)
8. F Lotufo-Neto M Trivedi ME Thase 1999 Meta-analyses of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression Neuropsychopharmacology 20 226 247 10.1016/S0893- 133X(98)00075-X 1:CAS:528:DyaK1MXhsleisrg%3D 10063483 (Pubitemid 29067402)
9. R Noyes Jr G Moroz JR Davidson, et al. 1997 Moclobemide in social phobia: a controlled dose-response trial J Clin Psychopharmacol 17 247 254 10.1097/00004714-199708000-00002 1:CAS:528:DyaK2sXltlKnurk%3D 9241002 (Pubitemid 27312421)
10. RG Priest R Gembrett W Roberts, et al. 1995 Reversible and selective inhibitors of monoamine-oxidase-A in mental and other disorders Acta Psychiatr Scand 386 Suppl 40 43 10.1111/j.1600-0447.1995.tb05923.x 1:STN:280: DyaK2M3jtlWitA%3D%3D
11. FM Quitkin JW Stewart PJ McGrath, et al. 1993 Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo Br J Psychiatry 163 Suppl 21 30 34
12. MV Rudorfer 1992 Monoamine oxidase inhibitors: reversible and irreversible Psychopharmacol Bull 28 45 57 1:STN:280:DyaK38zgt1ertQ%3D%3D 1609042
13. DV Sheehan J Ballinger G Jacobson 1980 Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms Arch Gen Psychiatry 37 51 59 1:STN:280:DyaL3c7gvVGitw%3D%3D 7352840
14. FR Schneier D Goetz R Campeas, et al. 1998 Placebo-controlled trial of moclobemide in social phobia Br J Psychiatry 172 70 77 10.1192/bjp.172.1.70 1:STN:280:DyaK1c7ps1egtw%3D%3D 9534836 (Pubitemid 28122531)
15. ME Thase MH Trivedi AJ Rush 1995 MAOIs in the contemporary treatment of depression Neuropsychopharmacology 12 185 219 10.1016/0893-133X(94)00058-8 1:STN:280:DyaK2Mzjs1KjsQ%3D%3D 7612154
16. P Tyrer C Shawcross 1988 Monoamine oxidase inhibitors in anxiety disorders J Psychiatric Res 22 Suppl 1 87 98 10.1016/0022-3956(88)90070-2
17. EH Uhlenhuth TD Warner W Matuzas 2002 Interactive model of therapeutic response in panic disorder: moclobemide, a case in point J Clin Psychopharmacology 22 275 284 10.1097/00004714-200206000-00008 1:CAS:528:DC%2BD38XksFCkurY%3D (Pubitemid 34546843)
18. M Versiani AE Nardi FD Mundim 1992 Pharmacotherapy of social phobia: a controlled study with moclobiemide and phenelzine Br J Psychiatry 161 353 360 10.1192/bjp.161.3.353 1:STN:280:DyaK3s%2Fgs1Orsg%3D%3D 1393304